TP53 and neoplasm: For patients with HER2-negative tumours they found genomic features associated with response to chemotherapy typically correlated with proliferation, TP53 mutation, tumour mutational burden, chromosomal instability, BRCA, HRD and APOBEC associated mutational signatures.